Key data from the 2023 European Thyroid Association annual meeting: De-escalation strategy in diagnosis and the treatment of differentiated thyroid carcinoma: Update after the 2023 ETA congress - 16/04/24
Doi : 10.1016/j.ando.2024.01.003
Magalie Haissaguerre a, Livia Lamartina b, Philippe Caron c, ⁎ 
a Service d’endocrinologie, diabétologie et nutrition, unité d’endocrinologie et oncologie endocrinienne, GH Sud - hôpital Haut-Lévêque, CHU de Bordeaux, Pessac, France
b Service de cancérologie endocrinienne, institut Gustave-Roussy, Villejuif, France
c Service d’endocrinologie et maladies métaboliques, hôpital Larrey, CHU de Toulouse, Toulouse, France
⁎Corresponding author. Department of Endocrinology and Metabolic Diseases, Cardiovascular and Metabolic Unit, CHU Larrey, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse cedex, France.Department of Endocrinology and Metabolic Diseases, Cardiovascular and Metabolic Unit, CHU Larrey24, chemin de Pouvourville, TSA 30030Toulouse cedex31059France
Il testo completo di questo articolo è disponibile in PDF.
Mappa
© 2024
Elsevier Masson SAS. Tutti i diritti riservati.
Vol 85 - N° 2
P. 155-157 - Aprile 2024 Ritorno al numero
Articolo precedente
- Key data from the 2023 European Thyroid Association annual meeting: Management of thyroid nodules
- Geneviève Crouzeix, Philippe Caron
- The key data from the 2023 European Thyroid Association Annual Meeting: Treatment of hyperthyroidism and subclinical hypothyroidism during pregnancy
- Philippe Caron
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?